HAYA Therapeutics doses first cohort in Phase 1 trial

Baxfendy approved in the US for hypertension

Freya Biosciences reports positive Phase 1 data for FB301

Elevara Medicines doses first patient in START-SYNERGY

May Health raises $11.7M to advance PCOS infertility device

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics

Henrijette Richter, managing partner at Sofinnova Partners, participated in the opening plenary panel discussion at the WuXi Global Forum 2022 on January 10. Marking the 10th anniversary of the event, the panel, led by Jorge Conde, general partner at Andreessen Horowitz, took a look back at 10 years of breakthroughs that are changing the game in R&D productivity before turning their focus on the future. Henrijette joined David Berry, founder and CEO of Valo Health; Diego Miralles, CEO of Laronde, and Roger Perlmutter, chairman and CEO of Eikon Therapeutics.
